This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-Learn About Coagulation Disorders
-What are Bleeding Disorders?
 History of Bleeding Disorders
 Types of Bleeding Disorders
 Types of Bleeds
 Bleeding Disorders and Women
 Caring for the Newly Diagnosed Child
 Psychosocial Issues
-Complications, including Inhibitors
 For Consumers
-For Providers
 The Challenge of Inhibitors
 Why Some Patients Develop Inhibitors
 Measuring Inhibitors
 Prognosis for Inhibitor Patients
 Social and Emotional Concerns
 Discussion Group
 Future Therapies
 What are Clotting Disorders?
 Comprehensive Medical Care - Hemophilia Treatment Centers
 Medical and Scientific Advisory Council
 Financial and Insurance Issues
 HANDI, NHF's Information Resource Center
 Web Links




Canclini M, Saviolo-Negrin N, Zanon E, Bertoletti R, Girolami A, Psychological aspects and coping in hemophilic patients: a case-control study. Hemophilia. 2003 Sep;9(5):619-24.

DiMichele D. Inhibitors: Resolving diagnostic and therapeutic dilemmas. Haemophilia. 2002, 8, 280-287.

Hedner U, Glazer S. Management of hemophilia patients with inhibitors. Hematol Oncol Clin North Am. 1992 Oct;6(5):1035-46.

Gill JC. The role of genetics in inhibitor formation. Blood (United States), Aug 1999, 82(2) p500-4

Goodeve A., The incidence of inhibitor development according to specific mutations—and treatment? Blood Coagul Fibrinolysis. 2003 Jun;14 Suppl 1:S17-21.

Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood (United States), Oct 1 2003, 102(7) p2358-63

Kreuz W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Blood (United States), Jun 2002, 28(3) p285-90

Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV., Catalytic antibodies to factor VIII in haemophilia A. Blood Coagul Fibrinolysis. 2003 Jun;14 Suppl 1:S31-4.

Nordfang, Mirella E Rasmussen, DK, Preparation for the treatment of hemophilia a inhibitor patients and a process for producing such a preparation. Biotechnol Adv. 1990;8(2):396.

Pandey GS, Panigrahi I, Phadke SR, Mittal B.
Knowledge and attitudes towards hemophilia: the family side and role of hemophilia societies. Community Genetics. 2003;6(2):120-2.

Shibata M, Shima M, Misu H, et al. Management of hemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates. Hemophilia, May 2003, 9(3) p269-71

Seremetis S., Dose optimization of recombinant factor VIIa in the reatment of acute bleeding in hemophilia-associated inhibitors. Blood Coagul Fibrinolysis. 2003 Jun;14 Suppl 1:S29-30.


This section of our Web site is sponsored by: